Cipla announced that Stempeutics Research, a group company of Manipal
Education and Medical Group and a Joint Venture with Cipla Group has been granted a US process patent for its novel stem-cell based drug Stempeucel by the United States Patent and Trademarks Office (USPTO).
Stempeucel will initially be used for the treatment of Critical Limb Ischemia (CLI) and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.
Powered by Capital Market - Live News
